Apyx Medical Announces Positive Clinical Data for Renuvion in Cellulite and Skin Laxity Treatment
summarizeSummary
Apyx Medical announced new clinical data showing its Renuvion system, combined with Avéli, significantly improves cellulite and skin laxity, validating its efficacy for a widespread aesthetic concern.
check_boxKey Events
-
New Clinical Study Published
Apyx Medical announced the publication of new clinical data in Aesthetic Surgery Journal Open Forum.
-
Renuvion Efficacy for Cellulite and Skin Laxity
The study highlighted a promising approach using Renuvion and Avéli, showing up to 81.8% patient improvement in cellulite appearance and objective reductions in dimple volume.
-
Tissue Remodeling Observed
Histological analysis demonstrated increased collagen and elastin, with improved dermal architecture and progressive tissue remodeling through 180 days post-treatment.
auto_awesomeAnalysis
This 8-K announces the publication of a new clinical study demonstrating significant improvements in cellulite and skin laxity using Apyx Medical's Renuvion system in combination with Avéli. The study showed up to 81.8% of patients improved, with objective reductions in dimple volume and increased collagen/elastin. This positive clinical validation strengthens the market position and potential adoption of Renuvion for common aesthetic concerns.
At the time of this filing, APYX was trading at $4.25 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $178M. The 52-week trading range was $1.38 to $4.50. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.